Vivos: Non-Surgical Solution for Obstructive Sleep Apnea | VVOS Clinical studies with Vivos devices have shown that 12 5–25% of patients may continue wearing a CPAP device All content found on the vivos com website—including text, images, audio, or other formats—is created for informational purposes only
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral . . . The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA, such as lowering Apnea Hypopnea Index scores Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children
Vivos | Obstructive Sleep Apnea Patients If you have NOT yet been diagnosed with OSA, complete our self-assessment survey to be connected with a Vivos-trained provider in your area Find out now if Vivos is right for you
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full . . . The three Vivos CARE devices open airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA, such as lowering Apnea Hypopnea Index scores Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children
Expand Your Practice: Become a Vivos Provider The Vivos Method is a multidisciplinary treatment protocol that uses cost-effective oral appliance technology prescribed by trained dentists and medical professionals to treat dentofacial abnormalities and or mild-to-moderate OSA
Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep . . . Vivos has agreed to pay up to $9 million for the SCN operating assets, including $6 million in cash and $1 5 million in Vivos common stock at closing An additional $1 5 million in Vivos common stock may be earned in the future if SCN achieves an agreed to financial milestone